VolitionRx has developed a new lateral flow finger-prick test for detecting NETosis in sepsis patients, showing strong correlation with its existing lab-based Nu.Q® NETs test. This rapid, minimally invasive test can be used at the bedside or in emergency rooms, enabling faster identification of high-risk patients and expanding access in regions lacking centralized labs. With sepsis affecting millions globally, this innovation could significantly improve early diagnosis and treatment, especially in low-income countries. VolitionRx plans to pursue partnerships to commercialize and expand this technology worldwide.
Bread Financial Holdings, formerly Alliance Data, is a U.S. financial services firm specializing in consumer payment and lending solutions. It maintains a strong financial position with a Tier 1 capital ratio near 14% and BB credit ratings, funding i...
BlackRock has purchased over $3.1 billion worth of Bitcoin and Ethereum in just eight days, acquiring 22,722 BTC and 385,633 ETH. This surge in buying coincides with a strong recovery in the broader cryptocurrency market. BlackRock's crypto funds, in...
Marvell Technology reported Q2 earnings and revenue above Wall Street expectations, with data center revenue up 46% year-over-year to $2.17 billion, driven by robust AI-related bookings. Despite this, shares fell 8% in premarket trading as investors ...
Cardano's ADA price rose 1.08% to $0.2147, maintaining support above $0.2004 amid optimism from the Ouroboros Leios protocol test. This test increased Cardano's transaction capacity by 500%, with four more testing phases before a planned mainnet upgr...
Hyperliquid Strategies raised $647 million in equity during its fiscal year ending June 30, 2026, using the funds to increase its HYPE token holdings to 29.3 million tokens valued at about $1.9 billion. The company reported net income of $305.5 milli...
